BETA: Please send your feedback!

Neurocrine Biosciences

NBIX:NAS

Biotechnology

$0
MID cap
$105.62 (0.95%)
-0.02%
since start of 2020
469.21
  • 5
  • 4
  • 3
  • 3
  • —
  • 2
  • 3
  • 4
  • 5
  • —
  • —
  • 4
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data & Privacy Protection
  • Consumer Health, Wellness & Safety
  • Employee Ownership, Satisfaction, Benefits & Pay
  • Workplace Health and Safety
  • Integrity of Corporate Governance
  • Ethical Practices
  • Usage of Conflict Materials
  • Forced Labor
  • Diversity of Corporate Leadership
  • —
  • 1
  • 2
  • 3
  • 4
  • 5

About

Neurocrine Biosciences, Inc. operates as a product based biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale on January, 1992 and is headquartered in San Diego, CA.
 website

Headquarters

12780 El Camino Real
San Diego, CA 92130
1.858.617.7600

Executives

Name Title Gender
Errol B. de Souza, PhD Founder Male
Kevin Charles Gorman, PhD, MBA Chief Executive Officer & Director Male
Christopher Flint O'Brien, MD Chief Medical Officer Male
Darin M. Lippoldt Chief Legal Officer Male
William H. Rastetter, PhD Chairman Male
Paul W. Hawran, CPA Founder Male
Wylie W. Vale, PhD Founder Male
Dimitri E. Grigoriadis, PhD Chief Research Officer Male
Bill Wilson Vice President-Information Technology & Operations Male
Malcolm Lloyd-Smith Chief Regulatory Officer Male
Jane Sorensen Head-Investor Relations Female
David-Alexandre C. Gros, MD, MBA President, Chief Operating & Financial Officer Male

Mindful Investing Summary

  • —
  • 1
  • 2
  • 3
  • 4
  • 5
  • Carbon Footprint
    — N/A
  • Pollution Prevention
    — N/A
  • Water Conservation
    — N/A
  • Data & Privacy Protection
    — N/A
  • Consumer Health, Wellness & Safety
    — N/A
  • Employee Ownership, Satisfaction, Benefits & Pay
    — N/A
  • Workplace Health and Safety
    — N/A
  • Integrity of Corporate Governance
    — N/A
  • Ethical Practices
    — N/A
  • Usage of Conflict Materials
    — N/A
  • Forced Labor
    — N/A
  • Diversity of Corporate Leadership
    2 N/A

Neurocrine Biosciences - Competitors and Related Companies

How Neurocrine Biosciences stacks up to its peers in the Biotechnology industry or with competing business segments.

Neurocrine Biosciences

NBIX:NAS

Biotechnology

$0
MID cap
$105.62 (0.95%)
-0.02%
since start of 2020
469.21
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • —
  • 2
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data & Privacy Protection
  • Consumer Health, Wellness & Safety
  • Employee Ownership, Satisfaction, Benefits & Pay
  • Workplace Health and Safety
  • Integrity of Corporate Governance
  • Ethical Practices
  • Usage of Conflict Materials
  • Forced Labor
  • Diversity of Corporate Leadership
  • —
  • 1
  • 2
  • 3
  • 4
  • 5

Paratek Pharmaceuticals

PRTK:NAS

Biotechnology

$120.84mm
SMALL cap
$3.63 (-0.01%)
-0.09%
since start of 2020
-0.95
  • 5
  • 4
  • 3
  • 3
  • —
  • 2
  • 3
  • 4
  • 5
  • —
  • —
  • 4
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data & Privacy Protection
  • Consumer Health, Wellness & Safety
  • Employee Ownership, Satisfaction, Benefits & Pay
  • Workplace Health and Safety
  • Integrity of Corporate Governance
  • Ethical Practices
  • Usage of Conflict Materials
  • Forced Labor
  • Diversity of Corporate Leadership
  • —
  • 1
  • 2
  • 3
  • 4
  • 5

Repligen

RGEN:NAS

Biotechnology

$5.26bn
SMALL cap
$101.01 (0.30%)
0.08%
since start of 2020
194.70
  • 5
  • 4
  • 3
  • 3
  • —
  • 2
  • 3
  • 4
  • 5
  • —
  • —
  • 4
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data & Privacy Protection
  • Consumer Health, Wellness & Safety
  • Employee Ownership, Satisfaction, Benefits & Pay
  • Workplace Health and Safety
  • Integrity of Corporate Governance
  • Ethical Practices
  • Usage of Conflict Materials
  • Forced Labor
  • Diversity of Corporate Leadership
  • —
  • 1
  • 2
  • 3
  • 4
  • 5

AbbVie

ABBV:NYS

Pharmaceuticals: Major

$130.12bn
MEGA cap
$87.99 (-0.01%)
-0.02%
since start of 2020
40.35
  • 5
  • 4
  • 3
  • 3
  • —
  • 2
  • 3
  • 4
  • 5
  • —
  • —
  • 4
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data & Privacy Protection
  • Consumer Health, Wellness & Safety
  • Employee Ownership, Satisfaction, Benefits & Pay
  • Workplace Health and Safety
  • Integrity of Corporate Governance
  • Ethical Practices
  • Usage of Conflict Materials
  • Forced Labor
  • Diversity of Corporate Leadership
  • —
  • 1
  • 2
  • 3
  • 4
  • 5

Eli Lilly

LLY:NYS

Pharmaceuticals: Major

$135.29bn
MEGA cap
$140.91 (1.33%)
0.07%
since start of 2020
31.67
  • 5
  • 4
  • 3
  • 3
  • —
  • 2
  • 3
  • 4
  • 5
  • —
  • —
  • 4
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data & Privacy Protection
  • Consumer Health, Wellness & Safety
  • Employee Ownership, Satisfaction, Benefits & Pay
  • Workplace Health and Safety
  • Integrity of Corporate Governance
  • Ethical Practices
  • Usage of Conflict Materials
  • Forced Labor
  • Diversity of Corporate Leadership
  • —
  • 1
  • 2
  • 3
  • 4
  • 5

Athersys

ATHX:NAS

Biotechnology

$200.53mm
MICRO cap
$1.28 (0.01%)
0.03%
since start of 2020
-4.11
  • 5
  • 4
  • 3
  • 3
  • —
  • 2
  • 3
  • 4
  • 5
  • —
  • —
  • 4
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data & Privacy Protection
  • Consumer Health, Wellness & Safety
  • Employee Ownership, Satisfaction, Benefits & Pay
  • Workplace Health and Safety
  • Integrity of Corporate Governance
  • Ethical Practices
  • Usage of Conflict Materials
  • Forced Labor
  • Diversity of Corporate Leadership
  • —
  • 1
  • 2
  • 3
  • 4
  • 5